Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sun Pharmaceutical Industries said that the US Food and Drug Administration has granted its subsidiary a tentative approval for an abbreviated new drug application (ANDA) to market a generic version of Cymbalta, duloxetine hydrochloride delayed-release capsules.
Subscribe to our email newsletter
Sun Pharma said that these generic duloxetine hydrochloride delayed-release capsules, 20mg (base), 30mg (base), and 60mg (base) are indicated in the treatment of major depressive disorder (MDD), generalised anxiety disorder (GAD) and diabetic peripheral neuropathic pain (DPNP).
Duloxetine (Cymbalta, Ariclaim, Xeristar, Yentreve) is a serotonin-norepinephrine reuptake inhibitor manufactured and marketed by Eli Lilly.